Objective: To investigate the effect of pretreatment with midazolam on myoclonus induced by etomidate injection. Methods: A meta-analysis was performed using Review Manager software, version 5.2. Two researchers independently searched PubMed, Cochrane Library, and Embase Õ databases for randomized controlled trials involving patients who underwent etomidate induced general anaesthesia with or without midazolam pretreatment, published between 1990 and 2016. Outcome measures comprised overall myoclonus incidence rate and incidence rate classified by degree of myoclonus following etomidate injection. Data were assessed using a fixed effects model. Results: Five studies, comprising 302 patients, were included for analysis. Overall incidence rate of etomidate injection-induced myoclonus was significantly lower in the pooled midazolam group versus controls (relative risk [RR] 0.34, 95% confidence interval [CI] 0.26, 0.44); Results subgrouped by degree of myoclonus showed significantly lower incidence in midazolam groups versus control groups for mild myoclonus (RR 0.56, 95% CI 0.39, 0.80); moderate myoclonus (RR 0.20, 95% CI 0.10, 0.41); and severe myoclonus (RR 0.12, 95% CI 0.04, 0.39). Conclusion: Midazolam can effectively prevent etomidate-induced myoclonus, and alleviate the degree of etomidate-induced myoclonus.
Introduction
Etomidate is a general anaesthesia drug that provides smooth anaesthesia induction conditions with little effect on the circulation and on breathing suppression. 1, 2 Etomidate is widely used in clinical anaesthesia, and is particularly suitable for use in patients with poor heart function. 3 Without other interventions, however, incidence of etomidateinduced myoclonus in patients undergoing anaesthesia induction may be as high as 50-80%. 4 Myoclonus can result in increased patient discomfort, for example, non-fasting patients tend to have a higher risk of reflux and aspiration; 5 in patients with open-globe injuries, myoclonus can result in increased intraocular pressure, giving rise to serious complications such as vitreous prolapse; 4 myoclonus may also induce epilepsy or increase focal epileptic activities; 6 and in cases of electrical cardioversion, continuous electroencephalographic monitoring may also be disturbed by myoclonus, thus affecting the treatment. 7 The effects of midazolam pretreatment on etomidate-induced myoclonus have been investigated in a number of clinical trials. The aim of the present study was to perform a review and meta-analysis of published data to analyse the effect of pretreatment with midazolam on myoclonus induced by etomidate injection.
Materials and methods

Study criteria and outcomes
To be included for analysis, studies were required to meet all of the following criteria: (1) randomized controlled trial design; (2) included patients aged 18 years who underwent general anaesthesia induced with etomidate; (3) and included a midazolam group and a placebo group. Animal studies, case reports, reviews and other publications, any publications with incomplete or repetitive data, and studies that were not randomized controlled trials were excluded.
Outcome measures comprised myoclonus incidence rate, and degree of myoclonus, following etomidate injection.
Search strategy
The following databases were searched for articles published between January 1990 and May 2016: PubMed, Cochrane Library and Embase Õ . The search was limited to English language articles and search terms comprised the following: midazolam, etomidate and its synonyms, myoclonus and its synonyms, randomized, controlled, and placebo.
Screening and data extraction
Search results were assessed by two researchers (CZ and YZ) who independently read titles and abstracts and excluded studies inconsistent with the inclusion criteria. Articles that met the inclusion criteria were then independently read in full by the two researchers, and the results were cross checked. Cases of disagreement were discussed between the two researchers and a third party (LR) if necessary until agreement was reached.
In cases of unclear or missing data, authors or corresponding authors were contacted by telephone or in writing to confirm or supplement the data as appropriate. For publications that met all inclusion criteria, the following information was extracted: (1) general information (including author, publication date, and other literature sources); (2) study setting and design (general information, interventions, and types of surgery undertaken); (3) outcome measures (overall myoclonus incidence rate, and degree of myoclonus following etomidate injection).
Quality assessment
Methodological quality of the included studies was evaluated according to the Jadad scale, 8 which scores factors such as randomization method, concealment of allocation and blinding. Out of a maximum score of 7 points: 4 points equated to a high-quality publication; and <4 points equated to a low-quality publication. For trials that had been supplemented and published several times, the publication with the most complete data was selected.
Statistical analyses
Meta-analyses were performed using Review Manager software, version 5.2 (Cochrane Collaboration, London, UK). Data were evaluated as overall myoclonus incidence rate, and myoclonus incidence rate in patients divided into subgroups according to degree of myoclonus:
4 mild, only mild fasciculation involving face and/or distal upper and/or lower extremities; moderate, marked movements of the face and/or limbs; or severe, involving limbs and trunk. Enumeration data are presented as relative risk (RR), and measurement data are presented as standardized mean difference (SMD), with a 95% confidence interval (CI), and test level of effect size a ¼ 0.05. Heterogeneity was assessed using 2 -test. A fixed effects model was used to conduct the meta-analysis when P > 0.1 and I 2 < 50%, indicating no heterogeneity. Following analysis of sources of heterogeneity, a random effects model was used to conduct combined effect analyses when P 0.1 and I 2 50%, indicating heterogeneity.
Results
Search results and study characteristics
The literature search and review results are presented in Figure 1 . The initial search resulted in 93 articles for screening. Following duplicate-checking and reading titles, abstracts, and original articles, five articles, 9-13 with a total of 302 patients were included in the meta-analysis. The pooled study group comprised 151 midazolamtreated patients and 151 normal saline-treated controls. Basic characteristics of the included studies are shown in Table 1 . All included studies followed the principle of randomization, and only one study 9 did not mention the blinding method. Except for one study, 11 results for all outcome measures were complete. None of the studies reported any patients leaving the study early, or lost to follow-up.
Meta-analysis results
All included studies, with a total of 302 patients, reported incidence rates of myoclonus following etomidate injection. No statistically significant heterogeneity was found (P ¼ 0.26, I
2 ¼ 25%), thus, a fixed effects model was used for meta-analysis. Overall myoclonus incidence rate following etomidate injection in patients pretreated with midazolam was significantly lower than that of controls without midazolam pretreatment (42/151 versus 123/151 patients; RR 0.34, 95% CI 0.26, 0.44; P < 0.00001; Figure 2 ).
All included studies reported the rates of mild etomidate-induced myoclonus. No statistically significant heterogeneity was found among any of the studies (P ¼ 0.5, I
2 ¼ 0%), thus a fixed effects model was used for meta-analysis. Mild myoclonus incidence rate following etomidate injection was significantly lower in patients pretreated with midazolam than in controls (33/151 versus 59/151 patients; RR 0.56, 95% CI 0.39, 0.80; P ¼ 0.001; Figure 3 ). All included studies reported the rates of moderate etomidate-induced myoclonus. No statistically significant heterogeneity was found among any of the studies (P ¼ 0.67, I
2 ¼ 0%), thus data were analysed using a fixed effects model. Moderate myoclonus incidence rate following etomidate injection was significantly lower in patients pretreated with midazolam than in controls (7/151 versus 39/151 patients; RR 0.20, 95% CI 0.10, 0.41; P < 0.0001; Figure 4 ). All included studies reported the rates of severe etomidate-induced myoclonus. Again, no statistically significant heterogeneity was found among any of the studies (P ¼ 0.93, I
2 ¼ 0%), thus a fixed effects model was used for meta-analysis. Incidence rate severe myoclonus following etomidate injection was significantly lower in patients pretreated with midazolam than in controls (1/151 versus 23/151 patients; RR 0.12, 95% CI 0.04, 0.39; P ¼ 0.0004; Figure 5 ).
Funnel plot analysis (data not shown) indicated that the results were asymmetrical. The fixed effects model, risk difference, and SMD, respectively were converted into a random effects model, odds ratio, and mean difference. Similar results were achieved (data not shown), indicating that the results of the meta-analysis were stable.
Discussion
The results of the current meta-analysis showed that midazolam is effective in reducing the incidence of etomidate-induced myoclonus, and mitigating the degree of etomidate-induced myoclonus.
Although the mechanism of etomidateinduced myoclonus remains unclear, there are several suggested hypotheses. One study 4 reported that etomidate-induced myoclonus was related to subcortical central depression, whereas another study 14 suggested that myoclonus may occur following etomidate injection due to the fact that the suppressive neuronal circuit was inhibited earlier than the excitatory neuronal circuit. Another potential mechanism 15 may be that etomidate acts on the *-aminobutyric acid (GABA) A receptor, thereby inhibiting the central nervous reticular activating system. Inhibition of neurotransmission through GABA A receptor activation may result in skeletal muscle control of relevant signal transmission, allowing the occurrence of autonomic nervous conduction. Midazolam is a water-soluble benzodiazepine. Its pharmacological characteristics includes fast-action, short half-life, rapid and complete absorption by muscle tissue and mucous membranes, and bioavailability >90%. 16 Under physiological pH, midazolam can quickly enter into the central nervous system through the blood brain barrier, thus rapidly playing its pharmacological role. 16 One potential reason for the prevention of etomidate-induced myoclonus by midazolam may be that midazolam interferes with neurohumor GABA reuptake, leading to accumulation of GABA. Small doses of midazolam have been found to readily suppress the effect of stimulation of the medullary reticular formation on electrochemical responses, leading to relaxation of central muscle, thus inhibiting or mitigating myoclonus. 13 The results of the present study are limited by a number of factors. The included studies were limited by quality, setting and design, and few were exactly matched with the inclusion criteria. The sample sizes were relatively small, and allocation concealment schemes were not reported, which may have given rise to selection or measurement bias. The midazolam dose, and time between midazolam administration and anaesthesia induction, varied between the studies. Direct comparative studies of midazolam and different treatment drugs and methods are scarce, thus, there is no strong evidence for which agent is the better choice in reducing myoclonus following etomidate-induced anaesthesia.
Treatment drugs and methods for preventing etomidate-induced myoclonus should be short-acting, and should not have significant effects on respiration or haemodynamics. Midazolam may meet these conditions, however, further randomized controlled trials with larger highquality samples are needed to confirm the present findings.
In summary, the present study shows that pretreatment with midazolam can effectively reduce the occurrence of myoclonus.
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